Novartis Investigative Site

Goodlettsville, Tennessee 37072-2301

0 studies enrolling now · 6 studies all time

What they study most

Hidradenitis Suppurativa, Moderate to Severe Chronic Plaque-Type Psoriasis, Moderate to Severe Palmoplantar Psoriasis, Moderate to Severe Plaque-type Psoriasis, Plaque Psoriasis

Studies at this site

• This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). — Completed
• Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis — Completed
• First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks — Completed
• 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis — Completed
• Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis — Completed
• Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens — Completed